7 assets in Erdheim-Chester Disease

Therapeutic assets addressing Erdheim-Chester Disease, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cobimetinib Erdheim-Chester Disease	Cancer Research UK	P2/3	B (56)
Dabrafenib Erdheim-Chester Disease	Cancer Research UK	P2/3	B (56)
Trametinib Erdheim-Chester Disease	Cancer Research UK	P2/3	B (56)
Vemurafenib Erdheim-Chester Disease	Cancer Research UK	P2/3	CCC (55)
hlx208 Erdheim-Chester Disease	Shanghai Henlius Biotech	P2	CCC (53)
q702 Erdheim-Chester Disease	Mayo Clinic	P1	CC (43)
Boclatixafortide Erdheim-Chester Disease	Memorial Sloan Kettering Cancer Center	Early P1	C (39)